{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:13:09Z","timestamp":1780413189911,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["102696"],"award-info":[{"award-number":["102696"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12859-019-2642-7","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T07:03:51Z","timestamp":1550473431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7467-1227","authenticated-orcid":false,"given":"Arnaud","family":"Amzallag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril H.","family":"Benes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"key":"2642_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nbt.1549","volume":"27","author":"J Leh\u00e0r","year":"2009","unstructured":"Leh\u00e0r J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, et al. Synergistic drug combinations improve therapeutic selectivity. Nat Biotechnol. 2009;27:659\u201366.","journal-title":"Nat Biotechnol"},{"key":"2642_CR2","doi-asserted-by":"crossref","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603.","DOI":"10.1038\/nature11003"},{"key":"2642_CR3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature11005","volume":"483","author":"MJ Garnett","year":"2012","unstructured":"Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570.","journal-title":"Nature"},{"key":"2642_CR4","first-page":"241","volume":"2","author":"L Zhao","year":"2010","unstructured":"Zhao L, Au JL-S, Wientjes MG. Comparison of methods for evaluating drug-drug interaction. Front Biosci Elite Ed. 2010;2:241.","journal-title":"Front Biosci Elite Ed"},{"key":"2642_CR5","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/1087057114521867","volume":"19","author":"W Zhao","year":"2014","unstructured":"Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth RE, Yang H. A new bliss independence model to analyze drug combination data. J Biomol Screen. 2014;19:817\u201321.","journal-title":"J Biomol Screen"},{"key":"2642_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140310","volume":"10","author":"AA Friedman","year":"2015","unstructured":"Friedman AA, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper ZA, Piris A, et al. Landscape of targeted anti-Cancer drug synergies in melanoma identifies a novel BRAFVEGFR\/PDGFR combination treatment. PLoS One. 2015;10:e0140310.","journal-title":"PLoS One"},{"key":"2642_CR7","doi-asserted-by":"crossref","unstructured":"Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3:e00149.","DOI":"10.1002\/prp2.149"},{"key":"2642_CR8","doi-asserted-by":"crossref","unstructured":"Tang J, Wennerberg K, Aittokallio T. What is synergy? The Saariselk\u00e4 agreement revisited. Front Pharmacol. 2015;6:181.","DOI":"10.3389\/fphar.2015.00181"},{"key":"2642_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"1939","unstructured":"Bliss CI. The toxicity of poisons applied jointly. Ann Appl Biol. 1939;26:585\u2013615.","journal-title":"Ann Appl Biol"},{"key":"2642_CR10","first-page":"331","volume":"47","author":"WR Greco","year":"1995","unstructured":"Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995;47:331\u201385.","journal-title":"Pharmacol Rev"},{"key":"2642_CR11","doi-asserted-by":"crossref","unstructured":"Cokol M, Chua HN, Tasan M, Mutlu B, Weinstein ZB, Suzuki Y, et al. Systematic exploration of synergistic drug pairs. Mol Syst Biol. 2011;7:544.","DOI":"10.1038\/msb.2011.71"},{"key":"2642_CR12","doi-asserted-by":"crossref","unstructured":"Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov. 2012;2:524\u201339.","DOI":"10.1158\/2159-8290.CD-11-0320"},{"key":"2642_CR13","doi-asserted-by":"crossref","unstructured":"Nyfeler B, Chen Y, Li X, Pinzon-Ortiz M, Wang Z, Reddy A, et al. RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth. PLoS One. 2012;7:e48548.","DOI":"10.1371\/journal.pone.0048548"},{"key":"2642_CR14","doi-asserted-by":"crossref","unstructured":"Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013;154:1151\u201361.","DOI":"10.1016\/j.cell.2013.08.003"},{"key":"2642_CR15","doi-asserted-by":"crossref","unstructured":"Neel BG, Gu H, Pao L. The \u2018Shp\u2019ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci. 2003;28:284\u201393.","DOI":"10.1016\/S0968-0004(03)00091-4"},{"key":"2642_CR16","doi-asserted-by":"crossref","unstructured":"Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, et al. Shp2 regulates Src family kinase activity and Ras\/Erk activation by controlling Csk recruitment. Mol Cell. 2004;13:341\u201355.","DOI":"10.1016\/S1097-2765(04)00050-4"},{"key":"2642_CR17","doi-asserted-by":"crossref","unstructured":"Sausgruber N, Coissieux M-M, Britschgi A, Wyckoff J, Aceto N, Leroy C, et al. Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases. Oncogene. 2015;34:2272\u20138.","DOI":"10.1038\/onc.2014.170"},{"key":"2642_CR18","doi-asserted-by":"crossref","unstructured":"Bostock M, Ogievetsky V, Heer J. D3 data-driven documents. IEEE Trans Vis Comput Graph. 2011;17:2301\u20139.","DOI":"10.1109\/TVCG.2011.185"},{"key":"2642_CR19","doi-asserted-by":"crossref","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995:289\u2013300.","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"2642_CR20","doi-asserted-by":"publisher","unstructured":"Hoaglin DC, Mosteller F, Tukey JW. Fundamentals of exploratory analysis of variance: Wiley; 2009. \n                    https:\/\/doi.org\/10.1002\/9780470316832\n                    \n                  .","DOI":"10.1002\/9780470316832"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-019-2642-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12859-019-2642-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-019-2642-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T10:25:31Z","timestamp":1582021531000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-019-2642-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2642"],"URL":"https:\/\/doi.org\/10.1186\/s12859-019-2642-7","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,18]]},"assertion":[{"value":"15 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"83"}}